Matrix Metalloproteinase-1 (MMP1) Upregulation Through Promoter Hypomethylation Enhances Tamoxifen Resistance in Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Mar 10

PMID 35267540

Authors

Hyeon Woo Kim

Jae Eun Park

Minjae Baek

Heejoo Kim

Hwee Won Ji

Sung Hwan Yun

Dawoon Jeong

Juyeon Ham

Sungbin Park

XinPei Lu

Han-Sung Kang

Sun Jung Kim

Affiliations

Soon will be listed here.

Abstract

Background: Tamoxifen (tam) is widely used to treat estrogen-positive breast cancer. However, cancer recurrence after chemotherapy remains a major obstacle to achieve good patient prognoses. In this study, we aimed to identify genes responsible for epigenetic regulation of tam resistance in breast cancer.

Methods: Methylation microarray data were analyzed to screen highly hypomethylated genes in tam resistant (tamR) breast cancer cells. Quantitative RT-PCR, Western blot analysis, and immunohistochemical staining were used to quantify expression levels of genes in cultured cells and cancer tissues. Effects of matrix metalloproteinase-1 (MMP1) expression on cancer cell growth and drug resistance were examined through colony formation assays and flow cytometry. Xenografted mice were generated to investigate the effects of MMP1 on drug resistance in vivo.

Results: MMP1 was found to be hypomethylated and overexpressed in tamR MCF-7 (MCF-7/tamR) cells and in tamR breast cancer tissues. Methylation was found to be inversely associated with MMP1 expression level in breast cancer tissues, and patients with lower MMP1 expression exhibited a better prognosis for survival. Downregulating MMP1 using shRNA induced tam sensitivity in MCF-7/tamR cells along with increased apoptosis. The xenografted MCF-7/tamR cells that stably expressed short hairpin RNA (shRNA) against MMP1 exhibited retarded tumor growth compared to that in cells expressing the control shRNA, which was further suppressed by tam.

Conclusions: MMP1 can be upregulated through promoter hypomethylation in tamR breast cancer, functioning as a resistance driver gene. MMP1 can be a potential target to suppress tamR to achieve better prognoses of breast cancer patients.

Citing Articles

Targeting extracellular matrix stiffness for cancer therapy.

Feng X, Cao F, Wu X, Xie W, Wang P, Jiang H Front Immunol. 2024; 15():1467602.

PMID: 39697341 PMC: 11653020. DOI: 10.3389/fimmu.2024.1467602.

Crosstalk of methylation and tamoxifen in breast cancer (Review).

Shen J, He Y, Li S, Chen H Mol Med Rep. 2024; 30(4).

PMID: 39129315 PMC: 11338244. DOI: 10.3892/mmr.2024.13304.

Hypomethylation-associated Sox11 upregulation promotes oncogenesis via the PI3K/AKT pathway in OLP-associated OSCC.

Liu Y, Cao P, Xiao L, Tang N, Fei W, Li X J Cell Mol Med. 2024; 28(14):e18556.

PMID: 39039706 PMC: 11263134. DOI: 10.1111/jcmm.18556.

Integrated bioinformatics analysis reveals upregulated extracellular matrix hub genes in pancreatic cancer: Implications for diagnosis, prognosis, immune infiltration, and therapeutic strategies.

Mogal M, Jame J, Sohel M, Mozibullah M, Mahmod M, Junayed A Cancer Rep (Hoboken). 2024; 7(4):e2059.

PMID: 38639039 PMC: 11027013. DOI: 10.1002/cnr2.2059.

Deciphering the role of wound healing genes in skin cutaneous melanoma: Insights into expression, methylation, mutations, and therapeutic implications.

Zhang Y, Gao C, Luo J, Khan A, Salem-Bekhit M, Salem M Int Wound J. 2024; 21(4):e14807.

PMID: 38591163 PMC: 11002634. DOI: 10.1111/iwj.14807.

References

Jang M, Park R, Park Y, Park Y, Lee J, Namkoong S . Contributes to Cell Cycle Progression and Cisplatin Resistance. Cancers (Basel). 2021; 13(16). PMC: 8394373. DOI: 10.3390/cancers13164066. View

Zheng Y, Sowers J, Houston K . IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation. Front Endocrinol (Lausanne). 2020; 11:233. PMC: 7218143. DOI: 10.3389/fendo.2020.00233. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Kastrati I, Joosten S, Semina S, Alejo L, Brovkovych S, Stender J . The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers. Mol Cancer Res. 2020; 18(7):1018-1027. PMC: 7335344. DOI: 10.1158/1541-7786.MCR-19-1082. View

Lee S, Park S, Lee H, Jeong D, Ham J, Choi E . ChIP-seq analysis reveals alteration of H3K4 trimethylation occupancy in cancer-related genes by cold atmospheric plasma. Free Radic Biol Med. 2018; 126:133-141. DOI: 10.1016/j.freeradbiomed.2018.08.004. View

Farooqui M, Bohrer L, Brady N, Chuntova P, Kemp S, Wardwell C . Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival. Mol Cancer. 2015; 14:138. PMC: 4517352. DOI: 10.1186/s12943-015-0408-z. View

Yang P, Li J, Peng C, Tan Y, Chen R, Peng W . TCONS_00012883 promotes proliferation and metastasis via DDX3/YY1/MMP1/PI3K-AKT axis in colorectal cancer. Clin Transl Med. 2020; 10(6):e211. PMC: 7568852. DOI: 10.1002/ctm2.211. View

Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D . Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res. 2007; 13(23):7029-36. DOI: 10.1158/1078-0432.CCR-07-0587. View

Coezy E, Borgna J, ROCHEFORT H . Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 1982; 42(1):317-23. View

10.

Jeong D, Ham J, Kim H, Kim H, Ji H, Yun S . ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer. Am J Cancer Res. 2021; 11(6):2568-2589. PMC: 8263635. View

11.

Kim S, Lee M, Lee M . Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat. 2020; 180(1):45-54. PMC: 7031178. DOI: 10.1007/s10549-019-05517-0. View

12.

Zhao Y, Jin L, Zhang X . Exosomal miRNA-205 promotes breast cancer chemoresistance and tumorigenesis through E2F1. Aging (Albany NY). 2021; 13(14):18498-18514. PMC: 8351670. DOI: 10.18632/aging.203298. View

13.

Stone A, Zotenko E, Locke W, Korbie D, Millar E, Pidsley R . DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. Nat Commun. 2015; 6:7758. PMC: 4510968. DOI: 10.1038/ncomms8758. View

14.

Ripoll C, Roldan M, Ruedas-Rama M, Orte A, Martin M . Breast Cancer Cell Subtypes Display Different Metabolic Phenotypes That Correlate with Their Clinical Classification. Biology (Basel). 2021; 10(12). PMC: 8698801. DOI: 10.3390/biology10121267. View

15.

Hamadneh L, Al-Lakkis L, Alhusban A, Tarawneh S, Abu-Irmaileh B, Albustanji S . Changes in Lactate Production, Lactate Dehydrogenase Genes Expression and DNA Methylation in Response to Tamoxifen Resistance Development in MCF-7 Cell Line. Genes (Basel). 2021; 12(5). PMC: 8160872. DOI: 10.3390/genes12050777. View

16.

Crump L, Wyatt G, Rutherford T, Richer J, Porter W, Lyons T . Hormonal Regulation of Semaphorin 7a in ER Breast Cancer Drives Therapeutic Resistance. Cancer Res. 2020; 81(1):187-198. PMC: 7878309. DOI: 10.1158/0008-5472.CAN-20-1601. View

17.

Yang X, Phillips D, FERGUSON A, Nelson W, Herman J, Davidson N . Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001; 61(19):7025-9. View

18.

Sieuwerts A, Inda M, Smid M, van Ooijen H, van de Stolpe A, Martens J . ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen. Cancers (Basel). 2020; 12(4). PMC: 7226576. DOI: 10.3390/cancers12040802. View

19.

Belachew E, Sewasew D . Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer. Front Endocrinol (Lausanne). 2021; 12:599586. PMC: 8030661. DOI: 10.3389/fendo.2021.599586. View

20.

Sachdeva M, Wu H, Ru P, Hwang L, Trieu V, Mo Y . MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene. 2010; 30(7):822-31. DOI: 10.1038/onc.2010.463. View